Ampio Pharmaceuticals, Inc. is contemplating filing for bankruptcy, as of November 14, 2023. According to company's SEC filing, the company raise substantial doubt as to its ability to continue as a going concern due to Its lack of operating revenue or cash inflows and cash resources on September 30, 2023. It incurred an accumulated deficit of $ 240.5 million as of September 30, 2023.

The Company expects to generate continued operating losses for the foreseeable future as it pursues the continued development and advancement of the OA-201 program. Additional financing may not be available and the stockholders may experience significant dilution of their ownership interests and the value of shares of its common stock could decline. It may implement further cost reduction and other cash-focused measures to manage liquidity and it may pursue a plan of liquidation or dissolution of Ampio or seek bankruptcy protection.